Annual CFI
-$94.25 M
+$20.87 M+18.13%
December 31, 2023
Summary
- As of February 23, 2025, VRDN annual cash flow from investing activities is -$94.25 million, with the most recent change of +$20.87 million (+18.13%) on December 31, 2023.
- During the last 3 years, VRDN annual CFI has fallen by -$43.77 million (-86.71%).
- VRDN annual CFI is now -433.92% below its all-time high of $28.23 million, reached on December 31, 2019.
Performance
VRDN Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$84.67 M
-$146.64 M-236.61%
September 30, 2024
Summary
- As of February 23, 2025, VRDN quarterly cash flow from investing activities is -$84.67 million, with the most recent change of -$146.64 million (-236.61%) on September 30, 2024.
- Over the past year, VRDN quarterly CFI has stayed the same.
- VRDN quarterly CFI is now -236.61% below its all-time high of $61.98 million, reached on June 30, 2024.
Performance
VRDN Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$335.45 M
-$132.71 M-65.46%
September 30, 2024
Summary
- As of February 23, 2025, VRDN TTM cash flow from investing activities is -$335.45 million, with the most recent change of -$132.71 million (-65.46%) on September 30, 2024.
- Over the past year, VRDN TTM CFI has stayed the same.
- VRDN TTM CFI is now -1115.06% below its all-time high of $33.05 million, reached on March 31, 2020.
Performance
VRDN TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
VRDN Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.1% | 0.0% | 0.0% |
| 3 y3 years | -86.7% | 0.0% | 0.0% |
| 5 y5 years | -215.2% | 0.0% | 0.0% |
VRDN Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -26.9% | +18.1% | -236.6% | +53.1% | -2176.8% | at low |
| 5 y | 5-year | -433.9% | +18.1% | -236.6% | +53.1% | -1115.1% | at low |
| alltime | all time | -433.9% | +18.1% | -236.6% | +53.1% | -1115.1% | at low |
Viridian Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$84.67 M(-236.6%) | -$335.45 M(+65.5%) |
| Jun 2024 | - | $61.98 M(-143.3%) | -$202.74 M(-9.5%) |
| Mar 2024 | - | -$143.04 M(-15.7%) | -$224.00 M(+137.7%) |
| Dec 2023 | -$94.25 M(-18.1%) | -$169.71 M(-453.3%) | -$94.25 M(-10.4%) |
| Sep 2023 | - | $48.04 M(+18.0%) | -$105.14 M(-4.9%) |
| Jun 2023 | - | $40.71 M(-406.2%) | -$110.53 M(-19.5%) |
| Mar 2023 | - | -$13.29 M(-92.6%) | -$137.28 M(+19.2%) |
| Dec 2022 | -$115.13 M(+55.0%) | -$180.60 M(-523.4%) | -$115.13 M(+681.4%) |
| Sep 2022 | - | $42.65 M(+205.5%) | -$14.73 M(-71.2%) |
| Jun 2022 | - | $13.96 M(+57.5%) | -$51.13 M(-33.0%) |
| Mar 2022 | - | $8.86 M(-111.0%) | -$76.30 M(+2.7%) |
| Dec 2021 | -$74.29 M(+47.2%) | -$80.21 M(-1383.2%) | -$74.29 M(+59.7%) |
| Sep 2021 | - | $6.25 M(-155.8%) | -$46.51 M(-11.9%) |
| Jun 2021 | - | -$11.21 M(-203.1%) | -$52.81 M(+26.9%) |
| Mar 2021 | - | $10.87 M(-120.7%) | -$41.61 M(-17.6%) |
| Dec 2020 | -$50.48 M(-278.8%) | -$52.43 M(>+9900.0%) | -$50.48 M(-664.2%) |
| Sep 2020 | - | -$53.00 K(<-9900.0%) | $8.95 M(-55.3%) |
| Jun 2020 | - | $0.00(-100.0%) | $20.02 M(-39.4%) |
| Mar 2020 | - | $2.00 M(-71.4%) | $33.05 M(+17.1%) |
| Dec 2019 | $28.23 M(-194.4%) | $7.00 M(-36.5%) | $28.23 M(-6.9%) |
| Sep 2019 | - | $11.02 M(-15.4%) | $30.32 M(+128.3%) |
| Jun 2019 | - | $13.03 M(-561.9%) | $13.28 M(-140.7%) |
| Mar 2019 | - | -$2.82 M(-131.0%) | -$32.63 M(+9.1%) |
| Dec 2018 | -$29.91 M | $9.09 M(-251.2%) | -$29.91 M(-23.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$6.01 M(-81.7%) | -$39.03 M(+18.0%) |
| Jun 2018 | - | -$32.89 M(>+9900.0%) | -$33.08 M(>+9900.0%) |
| Mar 2018 | - | -$95.00 K(+179.4%) | -$297.00 K(-128.7%) |
| Dec 2017 | $1.03 M(<-9900.0%) | -$34.00 K(-46.0%) | $1.03 M(-3.2%) |
| Sep 2017 | - | -$63.00 K(-40.0%) | $1.07 M(-5.6%) |
| Jun 2017 | - | -$105.00 K(-108.5%) | $1.13 M(-8.5%) |
| Mar 2017 | - | $1.24 M(>+9900.0%) | $1.24 M(<-9900.0%) |
| Dec 2016 | -$3000.00(-96.8%) | $0.00(0.0%) | -$3000.00(-88.5%) |
| Sep 2016 | - | $0.00(0.0%) | -$26.00 K(-13.3%) |
| Jun 2016 | - | $0.00(-100.0%) | -$30.00 K(-44.4%) |
| Mar 2016 | - | -$3000.00(-87.0%) | -$54.00 K(-43.2%) |
| Dec 2015 | -$95.00 K(-65.3%) | -$23.00 K(+475.0%) | -$95.00 K(-71.5%) |
| Sep 2015 | - | -$4000.00(-83.3%) | -$333.00 K(-1.5%) |
| Jun 2015 | - | -$24.00 K(-45.5%) | -$338.00 K(+6.3%) |
| Mar 2015 | - | -$44.00 K(-83.1%) | -$318.00 K(+16.1%) |
| Dec 2014 | -$274.00 K(-4666.7%) | -$261.00 K(+2800.0%) | -$274.00 K(+1690.8%) |
| Sep 2014 | - | -$9000.00(+125.0%) | -$15.30 K(+80.0%) |
| Jun 2014 | - | -$4000.00(<-9900.0%) | -$8500.00(-241.7%) |
| Mar 2014 | - | $0.00(-100.0%) | $6000.00(0.0%) |
| Dec 2013 | $6000.00(-105.0%) | -$2300.00(+4.5%) | $6000.00(-27.7%) |
| Sep 2013 | - | -$2200.00(-121.0%) | $8300.00(-21.0%) |
| Jun 2013 | - | $10.50 K(>+9900.0%) | $10.50 K(>+9900.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | -$119.40 K | - | - |
FAQ
- What is Viridian Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Viridian Therapeutics?
- What is Viridian Therapeutics annual CFI year-on-year change?
- What is Viridian Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Viridian Therapeutics?
- What is Viridian Therapeutics quarterly CFI year-on-year change?
- What is Viridian Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Viridian Therapeutics?
- What is Viridian Therapeutics TTM CFI year-on-year change?
What is Viridian Therapeutics annual cash flow from investing activities?
The current annual CFI of VRDN is -$94.25 M
What is the all time high annual CFI for Viridian Therapeutics?
Viridian Therapeutics all-time high annual cash flow from investing activities is $28.23 M
What is Viridian Therapeutics annual CFI year-on-year change?
Over the past year, VRDN annual cash flow from investing activities has changed by +$20.87 M (+18.13%)
What is Viridian Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of VRDN is -$84.67 M
What is the all time high quarterly CFI for Viridian Therapeutics?
Viridian Therapeutics all-time high quarterly cash flow from investing activities is $61.98 M
What is Viridian Therapeutics quarterly CFI year-on-year change?
Over the past year, VRDN quarterly cash flow from investing activities has changed by $0.00 (0.00%)
What is Viridian Therapeutics TTM cash flow from investing activities?
The current TTM CFI of VRDN is -$335.45 M
What is the all time high TTM CFI for Viridian Therapeutics?
Viridian Therapeutics all-time high TTM cash flow from investing activities is $33.05 M
What is Viridian Therapeutics TTM CFI year-on-year change?
Over the past year, VRDN TTM cash flow from investing activities has changed by $0.00 (0.00%)